-
hcup-us.ahrq.gov/reports/statbriefs/sb296-Payers-Maternal-ED-2019.pdf
January 01, 2019 - Expected Payers and Patient Characteristics of Maternal Emergency Department Care, 2019
1
STATISTICAL BRIEF #296
June 2022
Kimberly W. McDermott, Ph.D., Lawrence D. Reid, Ph.D., and
Pamela L. Owens, Ph.D.
Introduction
Maternal health coverage is an important element of health
i…
-
hcup-us.ahrq.gov/reports/statbriefs/sb204-Most-Expensive-Hospital-Conditions.jsp
May 01, 2016 - Skin and subcutaneous tissue infections
718
1.1
110
1.5
17
Short gestation, low birth weight … Medicaid-covered stays:
Cardiac and circulatory congenital anomalies
Short gestation, low birth weight
-
www.uspreventiveservicestaskforce.org/uspstf/recommendation/perinatal-depression-preventive-interventions
February 12, 2019 - depression is linked to an increased risk of preterm birth, small for gestational age newborn, and low birth weight … fatty acids demonstrated small statistically significant improvements in gestational length, mean birth weight
-
effectivehealthcare-admin.ahrq.gov/products/dietary-protein-intake/protocol
June 02, 2023 - that aim to treat participants who have already been diagnosed with the outcome of interest (except weight
-
www.uspreventiveservicestaskforce.org/uspstf/recommendation/high-blood-pressure-in-adults-screening-monitoring-october-2015
October 12, 2015 - Share to Facebook
Share to X
Share to WhatsApp
Share to Email
Print
archived
Final Recommendation Statement
High Blood Pressure in Adults: Screening
October 12, 2015
Recommendations made by the USPSTF are independent of the U.S. governmen…
-
www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/perinatal-depression-preventive-interventions
February 12, 2019 - depression is linked to an increased risk of preterm birth, small for gestational age newborn, and low birth weight … fatty acids demonstrated small statistically significant improvements in gestational length, mean birth weight
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/dietary-protein-intake-protocol-amendment.pdf
November 28, 2023 - aim to treat
participants who have
already been diagnosed
with the outcome of
interest (except weight
-
cds.ahrq.gov/taxonomy/term/69806
August 23, 2024 - Search All AHRQ Sites
Careers
Contact Us
Español
FAQs
Email Updates
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/bWme33U4raQYVZzafX8TjL
August 01, 2005 - Decrease in birth weight in relation to
maternal bone-lead burden. … O’Conno
r,
199967
(Fair)
Randomized
placebo-
controlled
double-blind
trial
DMSA (child weight … <15 kg) 1,000 mg
tid for 5 days,
followed by 100 mg
bid for 14 days
DMSA (child weight
>15 kg … For the
anthropometric measures of maternal nutritional
status, variables measuring gain in weight … (other significant birth weight predictors included maternal
nutritional status, parity, education
-
qualityindicators.ahrq.gov/Archive/News2009.aspx
January 27, 2010 - Measures moved to other SAS modules – PSI 17 (Birth trauma – Injury to Neonate) and PQI 9 (Low Birth Weight
-
www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/professionals/systems/long-term-care/resources/ontime/pruprev/factraining_slides.pptx
December 01, 2014 - Examples from Pressure Ulcer Prevention Reports:
Nutrition Risk Report
Risk criteria
Meal consumption
Weight
-
www.cahps.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-88-measure-1-section-5-attachment-4.pdf
January 01, 2011 - Patients Treated With Medication for ADHD Should
Have Their Height and Weight Monitored Throughout Treatment
-
www.cahps.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-4.pdf
January 01, 2011 - Patients Treated With Medication for ADHD
Should Have Their Height and Weight Monitored Throughout
-
www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-4.pdf
January 01, 2011 - Patients Treated With Medication for ADHD
Should Have Their Height and Weight Monitored Throughout
-
www.innovations.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-88-measure-1-section-5-attachment-4.pdf
January 01, 2011 - Patients Treated With Medication for ADHD Should
Have Their Height and Weight Monitored Throughout Treatment
-
www.innovations.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-4.pdf
January 01, 2011 - Patients Treated With Medication for ADHD
Should Have Their Height and Weight Monitored Throughout
-
www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-88-measure-1-section-5-attachment-4.pdf
January 01, 2011 - Patients Treated With Medication for ADHD Should
Have Their Height and Weight Monitored Throughout Treatment
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-88-measure-1-section-5-attachment-4.pdf
January 01, 2011 - Patients Treated With Medication for ADHD Should
Have Their Height and Weight Monitored Throughout Treatment
-
www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-4.pdf
January 01, 2011 - Patients Treated With Medication for ADHD
Should Have Their Height and Weight Monitored Throughout
-
www.monahrq.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-4.pdf
January 01, 2011 - Patients Treated With Medication for ADHD
Should Have Their Height and Weight Monitored Throughout